Bromodomain containing protein 4 (BRD4) and cancer therapy: A glimpse at dual-target drug development

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Bromodomain-containing protein 4 (BRD4) is a key epigenetic regulator involved in cancer development.
• BRD4 promotes oncogene transcription, cell cycle progression, DNA repair, immunosuppression, and telomere maintenance.
• Early BRD4 inhibitors like (+)-JQ1 show preclinical efficacy but face clinical resistance challenges.

Purpose of the Study:

• To review mechanisms of tumor resistance to BRD4-targeted therapies.
• To explore dual-target inhibitors as a strategy to overcome resistance and improve cancer treatment.

Main Methods:

• Literature review of BRD4 functions, resistance mechanisms, and novel therapeutic strategies.
• Analysis of dual-target inhibitor approaches combining BRD4 inhibition with other pathways.

Main Results:

• Tumor resistance to BRD4 inhibitors involves BRD4 protein stability, phosphorylation, and alternative signaling pathways.
• Dual-target inhibitors offer a promising strategy by simultaneously targeting BRD4 and other oncogenic pathways or epigenetic regulators.
• Approaches leveraging synthetic lethality, epigenetic regulation, and cell cycle disruption enhance therapeutic efficacy.

Conclusions:

• Understanding BRD4 resistance mechanisms is crucial for developing effective cancer therapies.
• Dual-target BRD4 inhibitors represent a promising strategy to overcome resistance and improve patient outcomes.
• Further optimization and clinical translation of dual-target therapies are expected to advance precise and efficient cancer treatment.